| 1. |
- Vieira-Silva, S., et al.
(författare)
-
Statin therapy is associated with lower prevalence of gut microbiota dysbiosis
- 2020
-
Ingår i: Nature. - : Springer Science and Business Media LLC. - 0028-0836 .- 1476-4687. ; 581:7808, s. 310-315
-
Tidskriftsartikel (refereegranskat)abstract
- Microbiome community typing analyses have recently identified the Bacteroides2 (Bact2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans1,2. Bact2 is characterized by a high proportion of Bacteroides, a low proportion of Faecalibacterium and low microbial cell densities1,2, and its prevalence varies from 13% in a general population cohort to as high as 78% in patients with inflammatory bowel disease2. Reported changes in stool consistency3 and inflammation status4 during the progression towards obesity and metabolic comorbidities led us to propose that these developments might similarly correlate with an increased prevalence of the potentially dysbiotic Bact2 enterotype. Here, by exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of the cross-sectional MetaCardis Body Mass Index Spectrum cohort (n=888), we identify statin therapy as a key covariate of microbiome diversification. By focusing on a subcohort of participants that are not medicated with statins, we find that the prevalence of Bact2 correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. Systemic inflammation levels in Bact2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of Bact2 as a dysbiotic microbiome constellation. We also observe that obesity-associated microbiota dysbiosis is negatively associated with statin treatment, resulting in a lower Bact2 prevalence of 5.88% in statin-medicated obese participants. This finding is validated in both the accompanying MetaCardis cardiovascular disease dataset (n = 282) and the independent Flemish Gut Flora Project population cohort (n=2,345). The potential benefits of statins in this context will require further evaluation in a prospective clinical trial to ascertain whether the effect is reproducible in a randomized population and before considering their application as microbiota-modulating therapeutics. © 2020, The Author(s), under exclusive licence to Springer Nature Limited.
|
|
| 2. |
- Fromentin, S., et al.
(författare)
-
Microbiome and metabolome features of the cardiometabolic disease spectrum
- 2022
-
Ingår i: Nature Medicine. - : Springer Science and Business Media LLC. - 1078-8956 .- 1546-170X. ; 28:2, s. 303-314
-
Tidskriftsartikel (refereegranskat)abstract
- By studying individuals along a spectrum of cardiometabolic disease and adjusting for effects of lifestyle and medication, this investigation identifies alterations of the metabolome and microbiome from dysmetabolic conditions, such as obesity and type 2 diabetes, to ischemic heart disease. Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages-acute coronary syndrome, chronic IHD and IHD with heart failure-and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.
|
|
| 3. |
- Paquette, J A, et al.
(författare)
-
D/H in the refractory organics of comet 67P/Churyumov-Gerasimenko measured by Rosetta/COSIMA
- 2021
-
Ingår i: monthly notices of the royal astronomical society. ; 504:4
-
Tidskriftsartikel (refereegranskat)abstract
- The D/H ratio is a clue to the origin and evolution of hydrogen-bearing chemical species in Solar system materials. D/H has been observed in the coma of many comets, but most such measurements have been for gaseous water. We present the first in situ measurements of the D/H ratios in the organic refractory component of cometary dust particles collected at very low impact speeds in the coma of comet 67P/Churyumov-Gerasimenko (hereafter 67P) by the COSIMA instrument onboard Rosetta. The values measured by COSIMA are spatial averages over an approximately 35 × 50 µm2 area. The average D/H ratio for the 25 measured particles is (1.57 ± 0.54) × 10−3, about an order of magnitude higher than the Vienna Standard Mean Ocean Water (VSMOW), but more than an order of magnitude lower than the values measured in gas-phase organics in solar-like protostellar regions and hot cores. This relatively high averaged value suggests that refractory carbonaceous matter in comet 67P is less processed than the most primitive insoluble organic matter (IOM) in meteorites, which has a D/H ratio in the range of about 1 to 7 × 10−4. The cometary particles measured in situ also have a higher H/C ratio than the IOM. We deduce that the measured D/H in cometary refractory organics is an inheritance from the presolar molecular cloud from which the Solar system formed. The high D/H ratios observed in the cometary particles challenges models in which high D/H ratios result solely from processes that operated in the protosolar disc.
|
|
